Over the past few decades, a growing body of research has revealed that microRNAs (miRNAs) play a crucial role in regulating the majority of mammalian protein-coding genes. These genes, in turn, control a broad array of cellular processes, such as differentiation, development, proliferation, and cellular senescence, through various regulatory mechanisms. Dysregulations in the biogenesis and functions of miRNAs have been linked to multiple human diseases, including lung, breast, hepatocellular, gastric, colorectal, and cervical cancers. Meanwhile, this review also discusses how miRNA modifications influence cancer biology by modulating the renin-angiotensin-aldosterone system (RAAS). These findings underscore the significant potential of miRNAs in cancers chemoradiotherapy resistance and RAAS .The present review aims to elucidate the association between miRNAs and cancer therapy resistance, with the goal of deepening our understanding of complex therapeutic mechanisms and informing clinical treatment strategies.
MathiyalaganPKeatingSTDuX-J, et al.Interplay of chromatin modifications and non-coding RNAs in the heart. Epigenetics2013; 9: 101–112.
2.
KleinbrinkEL, et al.Gestational age dependence of the maternal circulating long non-coding rna transcriptome during normal pregnancy highlights antisense and pseudogene transcripts. Front Genet2021; 12:760849
3.
SongWChenXWuH, et al.Circular RNAs as a novel class of potential therapeutic and diagnostic biomarkers in reproductive biology/diseases. Eur J Med Res2024; 29:643
4.
LiPMaXHuangD. Role of the lncRNA/Wnt signaling pathway in digestive system cancer: a literature review. Eur J Med Res2024; 29:447
5.
CostaFF. Non-coding RNAs: new players in eukaryotic biology. Gene2005; 357: 83–94.
6.
LeeRCFeinbaumRLAmbrosV. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell1993; 75: 843–854.
7.
WightmanBHaIRuvkunG. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell1993; 75: 855–862.
8.
CalinGADumitruCDShimizuM, et al.Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A.2002; 99: 15524–15529.
9.
AderintoNOlatunjiGKokoriE, et al.miR-210 in ischaemic stroke: biomarker potential, challenges and future perspectives. Eur J Med Res2024; 29:432
10.
SunYShangQ. Research hotspots and trends regarding microRNAs in hypertension: a bibliometric analysis. Clin Exp Hypertens2024; 46(1):2304017
11.
LingHFabbriMCalinGA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov.2013; 12: 847–865.
12.
VoliniaSCalinGALiuC-G, et al.A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A.2006; 103: 2257–2261.
13.
LuJGetzGMiskaEA, et al.MicroRNA expression profiles classify human cancers. Nature2005; 435: 834–838.
14.
NaeimzadehY, et al.Deregulated MicroRNAs involved in P53 signaling pathway in breast cancer with Focus on Triple-negative Breast Cancer. Curr Mol Pharmacol2023; 17:e18761429263841
15.
LiuD, et al.SP1-induced Circ_0017552 modulates colon cancer cell proliferation and apoptosis via up-regulation of NET1. Cancer Genet2024; 286-287: 1–10.
16.
TayYZhangJThomsonAM, et al.MicroRNAs to nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. nature2009; 458: 538.
17.
LytleJRYarioTASteitzJA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proc Natl Acad Sci U S A.2007; 104: 9667–9672.
18.
RobertsonNMYigitMV. The role of microRNA in resistance to breast cancer therapy. WIRES RNA2014; 5: 823–833.
19.
ZhuYYuFJiaoY, et al.Reduced miR-128 in breast tumor–initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res2011; 17: 7105–7115.
20.
LiangZWuHXiaJ, et al.Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol2010; 79: 817–824.
21.
BourguignonLY, et al.Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. (1083-351X (Electronic)).
22.
PogribnyIPFilkowskiJNTryndyakVP, et al.Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer2010; 127: 1785–1794.
23.
van 't VeerLJDaiHvan de VijverMJ, et al.Gene expression profiling predicts clinical outcome of breast cancer. Nature2002; 415: 530–536.
24.
ForouzanfarMHForemanKJDelossantosAM, et al.Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet2011; 378: 1461–1484.
25.
ChenY, et al.Hyperthermia/glutathione-triggered ferritin nanoparticles amplify the ferroptosis for synergistic tumor therapy. Materials Today Bio2024: 26:101085
26.
PourhanifehMHFarrokhi-KebriaHMostanadiP, et al.Anticancer properties of baicalin against breast cancer and other gynecological cancers: therapeutic opportunities based on underlying mechanisms. Curr Mol Pharmacol2024; 17:e18761429263063
27.
WangSOhD-YLeventakiV, et al.MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett2019; 465: 12–23.
28.
NiuJ, et al.DNA damage induces NF-κB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. (1083-351X (Electronic).
29.
SiMLZhuSWuH, et al.miR-21-mediated tumor growth. Oncogene2007; 26: 2799–2803.
30.
WangY, et al.Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. (1476-5594 (Electronic)).
31.
ShatsevaTLeeDYDengZ, et al.MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci2011; 124: 2826–2836.
32.
WuJ, et al.Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer. (1945-4589 (Electronic)).
33.
ParkEYChangELeeEJ, et al.Targeting of miR34a–NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res2014; 74: 7573–7582.
34.
LiuC, et al.The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. (1546-170X (Electronic)).
35.
LiY, et al.MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. (1538-7445 (Electronic)).
36.
GallardoENavarroAViñolasN, et al.miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis2009; 30: 1903–1909.
37.
YangX, et al.Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway. (2211-3835 (Print)).
38.
LeeJW, et al.MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. (1349-7006 (Electronic)).
39.
GeneraliD, et al.COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. (1532-1827 (Electronic)).
40.
BalanisN, et al.Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. (1083-351X (Electronic)).
41.
IsertL, et al.Cellular EMT-status governs contact guidance in an electrospun TACS-mimicking in vitro model. Materials Today Bio2025: 30:101401
42.
LiZ, et al.IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells. (1551-4005 (Electronic)).
43.
DanTShastriAAPalaganiA. miR-21 plays a dual role in tumor formation and cytotoxic response in breast tumors. Cancers (Basel)2021; 13: 888.
44.
PanG, et al.EMT-associated microRNAs and their roles in cancer stemness and drug resistance. (2523-3548 (Electronic)).
45.
DökümcüKSimonianMFarahaniRA-O. miR4673 improves fitness profile of neoplastic cells by induction of autophagy. (2041-4889 (Electronic)).
46.
JianX, et al.Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340. (1476-4598 (Electronic)).
47.
LiXWQiuSJZhangX. Overexpression of miR-215-3p sensitizes colorectal cancer to 5-fluorouracil induced apoptosis through regulating CXCR1. 2018.
48.
LiXWQiuSJZhangX. Overexpression of miR-215-3p sensitizes colorectal cancer to 5-fluorouracil induced apoptosis through regulating CXCR1. Eur. Rev. Med. Pharmacol. Sci2018; 22: 7240–7250.
49.
JiD, et al.Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer. (2213-6711 (Electronic)).
50.
QianX, et al.MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. (1551-4005 (Electronic)).
51.
FengCZhangLSunY, et al.GDPD5, A target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer. Biomed Pharmacother2018; 101: 945–952.
52.
HanP, et al.The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. (1476-4598 (Electronic)).
53.
SunW, et al.The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. (1838-7640 (Electronic)).
54.
YangY, et al.MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27. (1689-1392 (Electronic)).
55.
RasmussenMH, et al.miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells. (2041-1723 (Electronic)).
56.
ZetriniAE, et al.Targeting DNA damage repair mechanism by using RAD50-silencing siRNA nanoparticles to enhance radiotherapy in triple negative breast cancer. Materials Today Bio2024: 28:101206
57.
YangPXuJZhangG, et al.The long noncoding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway. J Gastroenterol Hepatol2017; 32: 837–845.
58.
WangD, et al.Activation of CXCL12/CXCR4 renders colorectal cancer cells less sensitive to radiotherapy via up-regulating the expression of survivin. (1535-3699 (Electronic)).
59.
HuHYangHFanS, et al.LncRNA HOTAIR promotes DNA damage repair and radioresistance by targeting ATR in colorectal cancer. Oncol Res2024; 32: 1335–1346.
60.
ChenX, et al.Exosome-mediated transfer of miR-93-5p from cancer-associated fibroblasts confer radioresistance in colorectal cancer cells by downregulating FOXA1 and upregulating TGFB3. (1756-9966 (Electronic)).
61.
WuY, et al.Downregulation of miR-1 in colorectal cancer promotes radioresistance and aggressive phenotypes. (1837-9664 (Print)).
62.
ZhangGLiuZZhongJ, et al.Circ-ACAP2 facilitates the progression of colorectal cancer through mediating miR-143-3p/FZD4 axis. Eur J Clin Investig2021; 51: e13607.
63.
KhoshinaniHMAfsharSPashakiAS, et al.Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line. Jpn J Radiol2017; 35: 664–672.
64.
WuQB, et al.Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy. (2049-9450 (Print)).
65.
XuSLiYLuY, et al.LZTS2 Inhibits PI3 K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. Cancer Lett2018; 420: 38–48.
66.
ChangL, et al.Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3 K/Akt/mTOR pathway in prostate cancer radioresistance. (2041-4889 (Electronic)).
67.
ChenX, et al.Exosomal miR-590-3p derived from cancer-associated fibroblasts confers radioresistance in colorectal cancer. (2162-2531 (Print)).
68.
WangH, et al.MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1). (1532-1827 (Electronic)).
69.
ChenY, et al.MicroRNAs as regulators of cisplatin resistance in lung cancer. Cell Physiol Biochem2015; 37: 1869–1880.
70.
LiQYangZChenM, et al.Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment. Int J Mol Med2016; 37: 1067–1074.
71.
LiuL, et al.PTEN inhibits non-small cell lung cancer cell growth by promoting G(0)/G(1) arrest and cell apoptosis. (1792-1074 (Print)).
72.
GkountakosA, et al.PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around. LID - 10.3390/cancers11081141 [doi] LID - 1141. (2072-6694 (Print)).
73.
GuoJ-HFangHYangJ, et al.MicroRNA-92b acts as an oncogene by targeting PTEN/AKT in NSCLC. Cell Biochem Funct2020; 38: 1100–1110.
74.
ShiLZhuWHuangY, et al.Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. Clin Transl Med2022; 12:e989
75.
ZhangP, et al.Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. (1349-7006 (Electronic)).
76.
WangpaichitrM, et al.Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer. LID - 183 [pii] LID - 10.4172/2168-9296.1000183 [doi]. (2168-9296 (Print)).
77.
FournelLWuZStadlerN, et al.Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett2019; 464: 5–14.
78.
WangC, et al.miRNA-328 overexpression confers cisplatin resistance in non-small cell lung cancer via targeting of PTEN. Mol Med Rep2018;18(5):4563-4570
79.
TravisWD, et al.The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol2015; 10: 1243–1260.
80.
SalamaJKVokesEE. New radiotherapy and chemoradiotherapy approaches for non–small-cell lung cancer. J Clin Oncol2013; 31: 1029–1038.
81.
RicardiUBadellinoSFilippiAR. Stereotactic body radiotherapy for early stage lung cancer: history and updated role. Lung Cancer2015; 90: 388–396.
82.
MaY, et al.Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3 K/Akt. (2314-6141 (Electronic)).
83.
JiangG, et al.lncRNA cytoskeleton regulator reduces non-small cell lung cancer radiosensitivity by downregulating miRNA-206 and activating prothymosin α. LID - 88 [pii] LID - 10.3892/ijo.2021.5268 [doi]. (1791-2423 (Electronic)).
84.
ZhuHYangWChengQ, et al.Circ_0010235 regulates HOXA10 expression to promote malignant phenotypes and radioresistance in non-small cell lung cancer cells via decoying miR-588. Balkan Med J2022; 39: 255–266.
85.
TangY, et al.Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. (1756-9966 (Electronic)).
86.
GongSLiYLvL, et al.Restored microRNA-519a enhances the radiosensitivity of non-small cell lung cancer via suppressing EphA2. Gene Ther2022; 29: 588–600.
87.
ParkG, et al.LDR-Induced miR-30a and miR-30b Target the PAI-1 Pathway to Control Adverse Effects of NSCLC Radiotherapy. (1525-0024 (Electronic)).
88.
MoradiM-TAltememyDAsadi-SamaniM, et al.The effect of celastrol in combination with 5-fluorouracil on proliferation and apoptosis of gastric cancer cell lines. Oncol Res2024; 32: 1231–1237.
89.
ShenLShanY-SHuH-M, et al.Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol2013; 14: e535–e547.
90.
RuanT, et al.A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer. (1178-6930 (Print)).
91.
OuyangL, et al.Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. (1365-2184 (Electronic)).
92.
LuoY, et al.Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. (1554-8635 (Electronic)).
93.
ZhangH, et al.CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. (1476-4598 (Electronic)).
94.
PongasGChesonBD. PI3K Signaling pathway in normal B cells and indolent B-cell malignancies. Semin Oncol2016; 43: 647–654.
95.
MacFarlaneAWT, et al.Enhanced NK-cell development and function in BCAP-deficient mice. (1528-0020 (Electronic)).
96.
ChenPGuoHWuX, et al.Epigenetic silencing of microRNA-204 by Helicobacter pylori augments the NF-κB signaling pathway in gastric cancer development and progression. Carcinogenesis2020; 41: 430–441.
97.
MakinoyaMMiyataniKMatsumiY, et al.Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis. Sci Rep2024; 14(1):10075
98.
JinLA-O, et al.Targeting Oncogenic miR-181a-2-3p Inhibits Growth and Suppresses Cisplatin Resistance of Gastric Cancer. (1179-1322 (Print)).
99.
ThrumurthySGChaudryMAHochhauserD, et al.The diagnosis and management of gastric cancer. BMJ2013; 347: f6367.
100.
HajjCGoodmanKA. Role of radiotherapy and newer techniques in the treatment of GI cancers. J Clin Oncol2015; 33: 1737–1744.
101.
TeyJ, et al.Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. (1949-2553 (Electronic)).
102.
ZimmermanALWuS. MicroRNAs, cancer and cancer stem cells. (1872-7980 (Electronic)).
103.
GarzonRCalinGACroceCM. MicroRNAs in cancer. Annu Rev Med2009; 60: 167–179.
104.
BrennerB, et al.MicroRNAs as a potential prognostic factor in gastric cancer. (2219-2840 (Electronic)).
105.
LiuJ, et al.MiRNA-4537 functions as a tumor suppressor in gastric cancer and increases the radiosensitivity of gastric cancer cells. (2165-5987 (Electronic)).
106.
ShenYNBaeI-SParkGH, et al.MicroRNA-196b enhances the radiosensitivity of SNU-638 gastric cancer cells by targeting RAD23B. Biomed Pharmacother2018; 105: 362–369.
107.
GuoFGuoRZhangL. Downregulation of lncRNA FOXD2-AS1 confers radiosensitivity to gastric cancer cells via miR-1913/SETD1A axis. Cytogenet Genome Res2022; 162: 10–27.
108.
ChenZGaoYJHouRZ, et al.MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci2019; 23: 171–180.
109.
ZhangX, et al.MiR-874-3p represses the migration and invasion yet promotes the apoptosis and cisplatin sensitivity via being sponged by long intergenic non-coding RNA 00922 (LINC00922) and targeting Glycerophosphodiester Phosphodiesterase Domain Containing 5 (GDPD5) in gastric cancer cells. (2165-5987 (Electronic)).
BrayF, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018; 68: 394–424.
112.
ZhangZ, et al.Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines. (1945-4589 (Electronic)).
113.
ChenXZhangXZhangL, et al.Amphiphilic Janus nanoparticles for imaging-guided synergistic chemo-photothermal hepatocellular carcinoma therapy in the second near-infrared window. Nanoscale2021; 13: 3974–3982.
114.
JinXJiangM-lWuZ-H, et al.Progress of individualized chemotherapy for gastric carcinoma under the guidance of genetic testing. Curr Med Chem2020; 27: 2322–2334.
115.
GaoJDaiCYuX, et al.Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. J Cell Biochem2021; 122: 1–99.
116.
WangG, et al.Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2. (1643-3750 (Electronic)).
117.
YeJ, et al.Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p. (1178-6930 (Print)).
118.
SunJ, et al.LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells. (1745-7270 (Electronic)).
119.
ChenHA, et al.Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells. (1945-4589 (Electronic)).
120.
LiR, et al.Dysregulation of the miR-325–3p/DPAGT1 axis supports HBV-positive HCC chemoresistance. Biochem Biophys Res Commun2019; 519: 358–365.
121.
ChenSYangCSunC, et al.miR-21-5p suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting FASLG. DNA Cell Biol2019; 38: 865–873.
122.
ZhangK, et al.PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. (2041-4889 (Electronic)).
123.
JuBL, et al.miR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition. Cell Mol Biol (Noisy-le-Grand).2015; 61: 12–16.
124.
WangJZhaoHYuJ, et al.MiR-92b targets p57kip2 to modulate the resistance of hepatocellular carcinoma (HCC) to ionizing radiation (IR) -based radiotherapy. Biomed Pharmacother2019; 110: 646–655.
125.
LuoJSiZ-ZLiT, et al.MicroRNA-146a-5p enhances radiosensitivity in hepatocellular carcinoma through replication protein A3-induced activation of the DNA repair pathway. American Journal of Physiology-Cell Physiology2018; 316: C299–C311.
126.
ShaoY, et al.MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma. (1525-0024 (Electronic)).
127.
FornariFPollutriDPatriziC, et al.In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis. Clin Cancer Res2017; 23: 3953–3965.
128.
PauwelsBWoutersAPeetersM, et al.Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncol2010; 6: 1485–1496.
129.
QianXTanCYangB, et al.Astaxanthin increases radiosensitivity in esophageal squamous cell carcinoma through inducing apoptosis and G2/M arrest. Dis Esophagus2017; 30: 1–7.
130.
LiebmannJCookJAFisherJ, et al.In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst.1994; 86: 441–446.
131.
YangZA-O, et al.miR-302a-3p Promotes Radiotherapy Sensitivity of Hepatocellular Carcinoma by Regulating Cell Cycle via MCL1. (1748-6718 (Electronic)).
132.
TangW, et al.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. (2059-3635 (Electronic)).
133.
WuCX, et al.Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. (1838-7640 (Electronic)).
134.
LiTT, et al.MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway. (1423-0127 (Electronic)).
135.
AbnetCCArnoldMWeiWQ. Epidemiology of Esophageal Squamous Cell Carcinoma. (1528-0012 (Electronic)).
136.
LiZ, et al.MiR-495 Inhibits Cisplatin Resistance and Angiogenesis in Esophageal Cancer by Targeting ATP7A. (1533-0338 (Electronic)).
137.
RenYJuQZhangJ, et al.MiR-302a-3p reduces cisplatin resistance of esophageal squamous cell carcinoma cells by targeting EphA2. J Chemother2023; 36: 72–81.
138.
ZuoJA-O, et al.MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma. (1759-7714 (Electronic)).
139.
LiuA, et al.Correction to: Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. (1476-4598 (Electronic)).
140.
BartelDP. MicroRNAs: target recognition and regulatory functions. (1097-4172 (Electronic)).
141.
AnconaE, et al.Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. (0008-543X (Print)).
142.
HanL, et al.MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1. (1349-7006 (Electronic)).
143.
ShiX, et al.miR-4443 promotes radiation resistance of esophageal squamous cell carcinoma via targeting PTPRJ. (1479-5876 (Electronic)).
144.
WuX, et al.Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. (1532-1827 (Electronic)).
145.
DoteHBurganWECamphausenK, et al.Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer Res2006; 66: 9211–9220.
146.
KariyaAFurusawaYYunokiT, et al.A microRNA-27a mimic sensitizes human oral squamous cell carcinoma HSC-4 cells to hyperthermia through downregulation of Hsp110 and Hsp90. Int J Mol Med2014; 34: 334–340.
147.
PanJ, et al.HSP90: A Novel Target Gene of miRNA-628-3p in A549 Cells. (2314-6141 (Electronic)).
148.
O'BrienK, et al.miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. (1949-2553 (Electronic)).
149.
ChoghaeiE, et al.Knockdown of microRNA-29a Changes the Expression of Heat Shock Proteins in Breast Carcinoma MCF-7 Cells. (1555-3906 (Electronic)).
150.
WangX, et al.MicroRNA-27a downregulates the expression of Hsp90 and enhances the radiosensitivity in esophageal squamous cell carcinoma. (1178-6930 (Print)).
151.
LiuZ, et al.A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma. (2001-1326 (Electronic)).
152.
LuoAZhouXShiX, et al.Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. Oncogene2019; 38: 4990–5006.
153.
QuC, et al.MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. (1551-4005 (Electronic)).
154.
PanF, et al.Sp1-mediated transcriptional activation of miR-205 promotes radioresistance in esophageal squamous cell carcinoma. (1949-2553 (Electronic)).
155.
ChenHYaoXDiX, et al.MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma. Cancer Lett2020; 483: 114–126.
156.
ZhangYChenWWangH, et al.Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3 K/AKT/mTOR signaling pathway. Cancer Chemother Pharmacol2019; 84: 1209–1218.
157.
SuH, et al.MicroRNA-301a targets WNT1 to suppress cell proliferation and migration and enhance radiosensitivity in esophageal cancer cells. Oncol Rep2019; 41: 599–607.
158.
SansoèGAragnoMAnandV. New viral diseases and new possible remedies by means of the pharmacology of the renin-angiotensin system. J Renin Angiotensin Aldosterone Syst2023; 2023:3362391
159.
ParkY, et al.Effect of renin-angiotensin system inhibitor in incident cancer among chronic hepatitis B patients: an emulated target trial using a nationwide cohort. J Renin Angiotensin Aldosterone Syst2024: 25:1-9
160.
JingTZengJ. Aldosterone-Cortisol co-secretion in different adrenal tumors: a case series. J Renin Angiotensin Aldosterone Syst2024: 25:1-5
161.
Valle-GarciaDPérez de la CruzVFloresI, et al.Use of microRNAs as diagnostic, prognostic, and therapeutic tools for glioblastoma. International Journal of Molecular2024; 25: 2464.
162.
AhmedSPCastresanaJSShahiMH. Glioblastoma and MiRNAs. Cancers (Basel)2021; 13: 1581.
163.
MahinfarPMansooriBRostamzadehD, et al.The role of microRNAs in multidrug resistance of glioblastoma. Cancers (Basel)2022; 14: 3217.
164.
WangLJiangCLiDM, et al.MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1. Oncotarget2016; 7: 2660–2671.
165.
OzpakL, et al.Anti-miRNA- 155 - 5p enhances the cytotoxic efficacy of temozolomide in brain cancer stem cells. Naunyn-Schmiedeberg's Arch Pharmacol2025. DOI:https://doi.org/10.1007/s00210-025-04135-6
166.
MilaniR, et al.Targeting miR-155-5p and miR-221-3p by peptide nucleic acids induces caspase-3 activation and apoptosis in temozolomide-resistant T98G glioma cells. Int J Oncol2019;55(1):59-68
167.
BayraktarRVan RoosbroeckK. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev2017; 37: 33–44.
168.
LaXZhangLLiZ, et al.(−)-Epigallocatechin gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-κB/miR-155-5p/MDR1 pathway. J Agric Food Chem2019; 67: 2510–2518.
169.
GaoY, et al.MicroRNA-155 increases colon cancer chemoresistance to cisplatin by targeting forkhead box O3. Oncol Lett2018;15(4):4781-4788
170.
GhorbaniA, et al.The prognostic, diagnostic, and therapeutic impact of long noncoding RNAs in gastric cancer. Cancer Genet2024; 282-283: 14–26.
171.
HuFRaoMZhangM, et al.Long non-coding RNA profiles in plasma exosomes of patients with gastric high-grade intraepithelial neoplasia. Exp Ther Med2021; 23(1):1
172.
GuoL-L. Competing endogenous RNA networks and gastric cancer. World J Gastroenterol2015; 21: 11680.
173.
TayYKatsLSalmenaL, et al.Coding-Independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell2011; 147: 344–357.
174.
HuarteM. The emerging role of lncRNAs in cancer. Nat Med2015; 21: 1253–1261.
175.
AhmadHKhanHHaqueS, et al.Angiotensin-converting enzyme and hypertension: a systemic analysis of various ACE inhibitors, their side effects, and bioactive peptides as a putative therapy for hypertension. J Renin Angiotensin Aldosterone Syst2023; 2023:7890188
176.
YiM, et al.TGF-β: a novel predictor and target for anti-PD-1/PD-L1 therapy. Front Immunol2022: 13:1061394
177.
FortuneKAliSMasurJ, et al.Impact of renin-angiotensin system inhibitors on response to PD1/L1 inhibitors in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer2025; 23: 102256.
178.
ChauhanVP, et al.Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun2013; 4:2516
179.
PinterMJainRK. Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy. Sci Transl Med2017; 9: eaan5616.
180.
ZhangFYaoZJinP, et al.A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator. Biomed Mater2023; 18: 035010.
181.
BoettgerTBeetzNKostinS, et al.Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest2009; 119: 2634–2647.
182.
EsfandyariYBDoustvandiMAAminiM, et al.MicroRNA-143 sensitizes cervical cancer cells to cisplatin: a promising anticancer combination therapy. Reprod Sci2021; 28: 2036–2049.
183.
HaoJZJRS. MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer. Am J Transl Res2018; 10: 525–534.
